PLK1-IN-9

PLK1-IN-9 (Compound M2) is an inhibitor for polo-like kinase 1 (PLK1), that inhibits PLK proteins modified with peptides 1010pT, cdc25c and PBIP, with IC50s of 1.6, 0.8 and 1.4 μM, respectively. PLK1-IN-9 inhibits proliferations of cancer cells HeLa, HL60, SNU387/499, HepG2, exhibits cytotoxicity and induces apoptosis. PLK1-IN-9 inhibits tumor growth in HepG2 xenograft mouse model[1].

Product Specifications

CAS Number

[893772-67-3]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Polo-like Kinase (PLK)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/plk1-in-9.html

Solubility

10 mM in DMSO

Smiles

CN1C2=C(N=C3C1=NC(NC3=O)=O)C=C(C(F)(F)F)C=C2

Molecular Formula

C12H7F3N4O2

Molecular Weight

296.20

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Kin K, et al., Pharmaceutical composition for preventing or treating cancer, containing activation inhibitor of plk1 as active ingredient. WO2020111325.